Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion

Published on October 18, 2021

Gilead's (GILD) application for breast cancer drug gets positive opinion for approval from EMA's CHMP.

Continue reading on website
Other news

Save 25% with TechCrunch+ Group Membership

October 18, 2021
We’re excited to announce Group Membership for TechCrunch+. The feature allows you to easily manage seats and payments for your team through a self-service interface. If your team joins through Group Membership, you’ll also save 25% or more on annual pricing. You must have at least five (5) users to take advantage of Group Membership.TechCrunch+ Group Membership can be found here.TechCrunch+ is a

3 Meme Stocks to Avoid in Q4 According to the POWR Ratings

October 18, 2021
Characterized by popularity, momentum, and high short interest, meme stocks have attracted much investor attention since the beginning of the year. However, since most meme stocks possess weak fundamentals, it...